Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) TrialDavid P. Steensma, Hagop M. Kantarjian, Maria R. Baer et al.|Journal of Clinical Oncology|2009Cited by 316
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A. Sekeres, Romina Brignardello‐Petersen, Gordon Guyatt et al.|Blood Advances|2020Cited by 191
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic reviewYaping Chang, Romina Brignardello‐Petersen, Gordon Guyatt et al.|PLoS ONE|2021Cited by 4
Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilusAmer M. Zeidan, Matteo Della Porta, Krzysztof Mądry et al.|Blood|2025Cited by 1
MDS-1047: RENEW Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate Elritercept in Participants With Transfusion-Dependent Anemia and Lower-Risk Myelodysplastic NeoplasmsRami S. Komrokji, Jen L. Salstrom, María Diez‐Campelo et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0